Toxicity of L-asparginase in children with advanced leukemia.
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects*; D002493:Central Nervous System Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D016883:Diabetic Ketoacidosis / Q000139:chemically induced; D004342:Drug Hypersensitivity; D005069:Evaluation Studies as Topic; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D008099:Liver / Q000187:drug effects; D010195:Pancreatitis / Q000139:chemically induced; D011241:Prednisone / Q000627:therapeutic use; D012008:Recurrence; D012075:Remission, Spontaneous; D013237:Stereoisomerism; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D001215:Asparaginase; D011241:Prednisone